Coronary Artery Disease, Dialysis, End Stage Renal Disease
Conditions
Keywords
coronary artery disease, end-stage renal disease, cardiac catheterizations, percutaneous coronary intervention, coronary artery bypass grafting, prognosis, metabolic Syndrome, revascularization, optimal medical therapy
Brief summary
Coronary artery disease (CAD) is the leading cause of death in end-stage renal disease (ESRD) patients requiring dialysis. There are limited data on clinical characteristics, treatment strategies and outcomes in this special patient population in China. As a nationwide, observational, multicenter cohort study, this study consecutively included ESRD patients on dialysis with significant CAD at 30 tertiary care centers in 12 provinces in China from January 2015 to June 2021. Patient data collected included demographics, comorbidities, cardiac history, cardiac function, location and severity of CAD, procedural information, medications, and clinical events.
Interventions
None listed
Sponsors
Aerospace Center Hospital
Beijing Chao Yang Hospital
Cangzhou Central Hospital of Tianjin Medical University
Civil Aviation General Hospital
Dongguan Tungwah Hospital
Emergency General Hospital
Fifth Affiliated Hospital of Xinjiang Medical University
First Central Hospital of Tianjin
Fuwai Yunnan Cardiovascular Hospital
Guangdong Provincial People's Hospital
Henan Provincial Chest Hospital
Ningbo No. 1 Hospital
Peking University People's Hospital
Peking University Shougang Hospital
People's Hospital of Xinjiang Uygur Autonomous Region
Tianjin Medical University Second Hospital
Shaoxing People's Hospital
Shengjing Hospital
First Affiliated Hospital of Xinjiang Medical University
the First Affiliated Hospital, Harbin Medical University
Zhejiang University
People's Hospital of Guangxi Zhuang Autonomous Region
The Third People's Hospital of Chengdu
Tianjin Medical University General Hospital
Tianjin Union Medicine Center
Tongji Hospital
West China Hospital
Xuanwu Hospital, Beijing
Wuhan University
China-Japan Friendship Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 50% or greater stenosis in any of three main coronary arteries or left main coronary artery on visual assessment of the coronary angiogram * Receive peritoneal dialysis or hemodialysis for more than 3 months
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause death | 12-month follow-up | All-cause deaths include cardiovascular death and non-cardiovascular death. Cardiovascular death is defined as death due to acute myocardial infarction, heart failure, sudden cardiac death, stroke, cardiovascular procedure, or cardiovascular hemorrhage. Non-cardiovascular death: any death not covered by the above definitions, such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide, or trauma. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major or clinically relevant nonmajor bleeding | From the hospital admission to 12-month follow-up | A bleeding event meeting Bleeding Academic Research Consortium criteria type 2, 3, or 5. |
| Cardiovascular death | From the hospital admission to 12-month follow-up | Cardiovascular death is defined as death due to acute myocardial infarction, heart failure, sudden cardiac death, stroke, cardiovascular procedure, or cardiovascular hemorrhage. |
| Non-fatal myocardial infarction | From the hospital admission to 12-month follow-up | Non-fatal myocardial infarction is confirmed in patients with ischemic symptoms, elevated serum cardiac biomarkers and/or distinctive ECG changes. |
| Major adverse cardiovascular events | From the hospital admission to 12-month follow-up | A composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. |
| Major bleeding | From the hospital admission to 12-month follow-up | A bleeding event meeting Bleeding Academic Research Consortium criteria type 3, or 5. |
| Clinically relevant nonmajor bleeding | From the hospital admission to 12-month follow-up | A bleeding event meeting Bleeding Academic Research Consortium criteria type 2. |
| Follow-up major adverse cardiovascular and clinical events | From the hospital admission, and up to 10 years | We will follow up the patients by telephone and outpatient service to know the all-cause mortality (cardiovascular and non-cardiovascular) and cardiovascular events. |
| Non-fatal myocardial stroke | From the hospital admission to 12-month follow-up | Non-fatal myocardial stroke is confirmed as a new neurological deficit attributed to a vascular cause in the central nervous system with imaging evidence by computed tomography or magnetic resonance imaging. |
Countries
China
Outcome results
None listed